Home infusion for myeloma drug passes early safety check
NCT ID NCT05041933
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tested whether the multiple myeloma drug carfilzomib can be safely given at home instead of in a hospital. Seventeen patients received their first cycle in the clinic and later cycles at home, with nurses administering the short infusion. The main goal was to see if the process followed safety rules without errors. If it works, this model could make treatment more convenient for patients and reduce hospital burden.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
carfilzomib (a chemotherapy drug given as a short intravenous infusion)
What this could lead to
If successful, this could show that giving certain chemotherapy infusions at home is safe and practical, potentially improving patient quality of life and reducing hospital visits.
What could go wrong
This is a very small pilot study (17 people) that only looked at whether the process works without errors. It does not test if the drug itself is effective or safe, and results may not apply to other drugs or regions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Limoges Hospital
Limoges, 87 042, France